These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33991350)

  • 1. Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.
    Kurosawa K; Rossenu S; Biewenga J; Ouwerkerk-Mahadevan S; Willems W; Ernault E; Kambili C
    J Clin Pharmacol; 2021 Oct; 61(10):1344-1355. PubMed ID: 33991350
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Yu X; Gao X; Li C; Luo J; Wen S; Zhang T; Ma Y; Dong L; Wang F; Huang H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
    Svensson EM; Murray S; Karlsson MO; Dooley KE
    J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.
    Erber J; Weidlich S; Tschaikowsky T; Rothe K; Schmid RM; Schneider J; Spinner CD
    BMC Infect Dis; 2020 May; 20(1):365. PubMed ID: 32448204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections.
    Magis-Escurra C; Alffenaar JW; Hoefnagels I; Dekhuijzen PN; Boeree MJ; van Ingen J; Aarnoutse RE
    Int J Antimicrob Agents; 2013 Sep; 42(3):256-61. PubMed ID: 23837923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.
    Healan AM; Griffiss JM; Proskin HM; O'Riordan MA; Gray WA; Salata RA; Blumer JL
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.
    Martin A; Godino IT; Aguilar-Ayala DA; Mathys V; Lounis N; Villalobos HR
    J Med Microbiol; 2019 Aug; 68(8):1137-1139. PubMed ID: 31210631
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.
    Omar S; Whitfield MG; Nolan MB; Ngom JT; Ismail N; Warren RM; Klopper M
    J Antimicrob Chemother; 2024 Feb; 79(2):211-240. PubMed ID: 38134888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
    Dooley KE; Park JG; Swindells S; Allen R; Haas DW; Cramer Y; Aweeka F; Wiggins I; Gupta A; Lizak P; Qasba S; van Heeswijk R; Flexner C;
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):455-62. PubMed ID: 22126739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method.
    Kotwal P; Magotra A; Dogra A; Sharma S; Gour A; Bhatt S; Wazir P; Singh PP; Singh G; Nandi U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1112():48-55. PubMed ID: 30851617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria.
    Aguilar-Ayala DA; Cnockaert M; André E; Andries K; Gonzalez-Y-Merchand JA; Vandamme P; Palomino JC; Martin A
    J Med Microbiol; 2017 Aug; 66(8):1140-1143. PubMed ID: 28749330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
    Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
    van Heeswijk RP; Dannemann B; Hoetelmans RM
    J Antimicrob Chemother; 2014 Sep; 69(9):2310-8. PubMed ID: 24860154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.
    Philley JV; Wallace RJ; Benwill JL; Taskar V; Brown-Elliott BA; Thakkar F; Aksamit TR; Griffith DE
    Chest; 2015 Aug; 148(2):499-506. PubMed ID: 25675393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment.
    Koele SE; van Beek SW; Maartens G; Brust JCM; Svensson EM
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0174921. PubMed ID: 35007141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.